AnaptysBio Inc (ANAB)
NASDAQ:ANAB
ANAB Stock Chart & Stats
$62.72
-$0.23(-1.55%)
At close: 4:00 PM EST
$62.72
-$0.23(-1.55%)
Day’s Range― - ―
52-Week Range$15.40 - $68.39
Previous CloseN/A
Volume154.73K
Average Volume (3M)554.92K
Market Cap
$1.80B
Enterprise Value$1.86B
Total Cash (Recent Filing)$311.64M
Total Debt (Recent Filing)$290.64M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
May 07, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.58
Shares Outstanding28,748,255
10 Day Avg. Volume732,208
30 Day Avg. Volume554,924
Financial Highlights & Ratios
PEG Ratio1.12
Price to Book (P/B)36.21
Price to Sales (P/S)5.74
P/FCF Ratio68.70
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue7.95
Enterprise Value/Gross Profit8.03
Enterprise Value/Ebitda27.93
Forecast
1Y Price Target
$83.57Price Target Upside33.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.94
Revenue Forecast (FY)$111.51M
Bulls Say, Bears Say
Bulls Say
Clinical Data ReadoutTopline results from the ANB033 phase one b trial in celiac disease could validate the drug's ability to prevent symptoms and support mucosal healing, strengthening its commercial potential.
Corporate RestructuringPlanned separation into a royalty company and a biopharma company may unlock shareholder value by letting each entity follow focused strategies and clearer valuation methods.
Pipeline Funding And Partnership PotentialStrong mid stage efficacy for rosnilimab in rheumatoid arthritis combined with plans to fund advancement through strategic outside capital could attract partners and reduce internal financing needs.
Bears Say
Analyst Conflict Of InterestDisclosure that the research firm conducts business with covered companies raises concern that analyst reports may be biased, reducing confidence in published assessments.
Class Level Therapeutic RiskDiscontinuation of a peer company's CD122 antagonist program highlights class level safety or efficacy concerns that could increase regulatory uncertainty for similar therapies.
Royalty Revenue Legal RiskAn ongoing legal dispute with the partner GSK creates downside risk to expected royalty revenues while breach claims remain unresolved.
AnaptysBio News
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $15.40 and its highest was $68.39 in the past 12 months.
What is AnaptysBio Inc’s market cap?
AnaptysBio Inc’s market cap is $1.80B.
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is May 07, 2026 which is in 43 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on Mar 03, 2026. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.863 by $0.717.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -0.96.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 28,748,255 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of $1.58 in its last earnings report, beating expectations of $0.863. Following the earnings report the stock price went up 14.613%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Currently, no hedge funds are holding shares in ANAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AnaptysBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$83.57 (33.25% Upside)
$83.57 (33.25% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 17.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $530.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
267.21%
12-Months-Change
Fundamentals
Return on Equity
1813.84%
Trailing 12-Months
Asset Growth
-24.69%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB Stock 12 Month Forecast
Average Price Target
$83.57
▲(33.25% Upside)
Technical Analysis
Meiragtx Holdings
―
Keros Therapeutics
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Terns Pharmaceuticals
―
Ownership Overview
Currently, No data available
---